Ready-to-Use mRNA Solutions: High-Performance Tools for Drug Development and Therapeutic Innovation

Before a single dose of mRNA ever reaches a cell, most labs go through the same expensive detour: weeks spent titrating T7 transcription conditions, troubleshooting capping efficiency that stalls at 70–80%, and rebuilding a purification protocol every time the construct changes. A standard mRNA can take two to three weeks to validate end-to-end — longer for saRNA or circRNA, where a single failed capping run means restarting the IVT step from scratch.

That validation cycle is the real cost of "building from scratch" — and it's the bottleneck Hzymes' ready-to-use mRNA is built to remove. Not by promising a shortcut on quality, but by shipping mRNA that has already cleared the transcription, capping, and purification steps most teams spend weeks re-optimizing: instead of the 70–80% capping efficiency most in-house workflows plateau at, every batch we ship clears a validated bar of >90% integrity and >97% capping rate.

A note on scope: this article covers the mRNA molecule itself — transcription, capping, and purification. If you’re evaluating delivery formats and LNP formulation specifically, that’s covered in our companion piece on ready-to-use LNP encapsulation kits.

Features

1.   Stable to handle. Store at 2–8°C for up to a month, with tolerance for 10+ freeze-thaw cycles — no special handling required between experiments.

2.   A validated performance bar. Integrity ≥90%, capping rate ≥97% on every batch — not a best-case number, a specification.

3.   Verified by cell expression. Every product is functionally tested, with protein expression benchmarked against competing products, not just measured on a Bioanalyzer trace.

4.   In stock, short lead time. A standard catalog spans the constructs teams reach for most often, so most orders ship without a custom synthesis wait.

Hzymes mRNA is commonly used at the cell-experiment stage, as an animal-study control, during purification process development, and for filler/formulation screening. Beyond the standard catalog below, we also offer custom mRNA synthesis for constructs not yet in stock.

Product Portfolio at a Glance

Full specs and COAs for each product are available on their individual product pages.

EGFP mRNA

1.      Integrity >90%

2.      Capping rate >90%

3.      High protein expression in cells.

The protein expression of EGFP mRNA is high and can last for at least 72 hours.

Fluc mRNA

1.        Good stability: Can be stored at 2-8°C for one month and can be frozen and thawed more than 10 times.

2.        Excellent performance: Integrity can reach 90%, and cap rate is above 98%.

3.        Product verified by cell expression: Protein expression is higher than that of competing products.

4.        Complete product range and stable supply: Available in stock with short delivery times.

The protein expression of Fluc mRNA is high in different cells

Fluc mRNA-LNP was intramuscularly injected into a mouse (6-8week, female) and live imaging. The protein expression of Fluc mRNA is high in vivo.

Cas9 mRNA

1.      Integrity >90%

2.      Capping rate >90%

3.      High protein expression in vitro.

Cas9 protein was successfully expressed with cas9 mRNA (N1-UTP) in 293T cells.

COVID-19 RBD (1000nt) mRNA

1.      Integrity >85%

2.      Capping rate >90%

3.      High protein expression in vitro.

RBD protein can be successfully expressed by RBD mRNA in 293T cells.

COVID-19 Spike (4000 nt) mRNA

1.      Integrity>85%

2.      Capping rate >90%

3.      High protein expression in vitro.

Spike protein can be successfully expressed by Spike mRNA in 293T cells.

Human EPO mRNA

1.      Integrity>90%

2.      Capping rate >90%

3.      High protein expression in vitro.

It is proved that the hEPO protein can be successfully expressed in hEPO mRNA in293T cells. The hEPO protein secretion was competent, and the expression was much higher in the supernatant than intracellular.

Mouse EPO mRNA

1.      Integrity >90%

2.      Capping rate >90%

3.      High protein expression in vitro.

It was demonstrated that the mEPO protein can be successfully expressed by mEPO mRNA in 293T cells. The mEPO protein was secreted highly, with much higher expression in the supernatant than intracellular.

EGFP saRNA

1.      Integrity >90%

2.      Long expression period: >26 days

3.      High protein expression in vitro.

It has been shown that EGFP saRNA can be expressed for up to 26 days, longer and in lower doses compared with linear EGFP MRNA.

circRNA eGFP

1.        Good stability: Can be stored at 2-8°C for one month and can be frozen and thawed more than 10 times.

2.        Excellent performance: Integrity can reach 90%, and cap rate is above 98%.

3.        Product verified by cell expression: Protein expression is higher than that of competing products.

4.        Complete product range and stable supply: Available in stock with short delivery times.

circRNA Fluc

Where This Fits in mRNA Drug Development

Our mRNA products are commonly used for:

• In vitro transcription and protein expression screening
• Providing the mRNA input for LNP formulation and encapsulation testing (not LNP formulation itself — see our companion article on ready-to-use LNP encapsulation)
• Immunogenicity & efficacy studies
• Cell line engineering and reporter assays
• Preclinical proof-of-concept work

Why Hzymes?

Decades of experience in nucleic acid technologies sit behind every batch — high-quality synthesis, rigorous QC, and fast turnaround, so your mRNA R&D program isn’t waiting on your raw material supplier.